Schizophrenia
Conditions
Brief summary
The objective of this study is to demonstrate that there is a benefit in switching chronic schizophrenic patients from conventional antipsychotic to olanzapine in terms of efficacy, neurological safety and patient's outcome.
Interventions
DRUGolanzapine
DRUGhaloperidol
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Schizophrenic patient meeting the DSM-IV diagnostic criteria more than one year ago and treated with antipsychotic for at least 1 year. Outpatient (or patient admitted to hospital for social or logistic reasons). Patient receiving a stable dose of the same conventional antipsychotic for at least 8 weeks before visit 1. Patient presenting a PANSS score equal or greater than 49 at Visit 2. Patient considered by the investigator as possible candidates for a switch, owing to inadequate efficacy or poor safety of the current treatment.
Exclusion criteria
Patient presenting a schizophreniform or a schizo-affective disorder according to the DSM-IV diagnostic criteria, or any other disorder from Axis I of the DSM-IV, or a disorder from Axis II (limit personality), substance dependence or substance abuse. Administration of an atypical antipsychotic drug during the 8 weeks preceding V1. History of resistance to antipsychotic drugs Hospitalization in a psychiatric unit or in a psychiatric emergency department within the 8 weeks preceding the beginning of the study. Presence of serious unstable disease, such as a fatal outcome or hospitalization in an intensive care unit, is foreseeable within a period of 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy measure is defined as relapse. Relapse is defined by the presence of at least one of the following criteria: | — |
| Psychiatric hospitalization. | — |
| A 25% increase in the total score on the PANSS scale (Kay SR et al. 1987) in relation to the score obtained at the baseline visit (Visit 2). | — |
| A major deterioration in clinical condition, defined by a score of 6 (much worse) or 7 (very much worse) on the CGI-I scale (Clinical Global Impression-Improvement) | — |
| Suicide attempt requiring medical treatment and/or jeopardizing vital prognosis (self-mutilation, ingestion of a toxic substance, defenestration, self-mutilation with suicidal intent). | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive and negative symptom scale : PANSS | — |
| Patient's quality of life: S-QOL | — |
| Schizophrenic Communication Disorder Rating Scale: SCD | — |
| Clinical global impression scale: CGI [Clinical global impression-severity of illness (CGI-S); Clinical global impression-improvement of illness (CGI-I); Clinical Global Impression scale - Psychic distress] | — |
| Social Interactions measurement tools | — |
| Intention Reading Task in a real-life situation | — |
| Patient Outcome based on Preference Tool: POP | — |
| The following secondary efficacy criteria will be measured at the times indicated in the Schedule of Events | — |
Countries
France
Outcome results
None listed